We therefore determined the frequency of antigen-specific Th17 cells in the CNS by ELISpot. After MOG 35-55 -peptide specific stimulation of equal numbers of CNS-derived T cells, we observed a strong reduction in antigen-specific IL-17 producing, but interestingly not IFN- producing, CD4 + T cells (Fig. 1) . In light of these results, we next investigated the influence of PPAR on CD4 + Th differentiation. To focus exclusively on the effect of PPAR in T cells, we used stimulation with CD3/CD28 in the absence of antigen-presenting cells. Interestingly, PPAR activation by PIO selectively inhibited Th17 differentiation induced by TGF- and IL-6, whereas IL-12-induced Th1 differentiation was completely unaffected (Fig. 1 d; Fig. S1 ). To obtain unequivocal evidence for the role of PPAR for Th17 differentiation, we generated T cell-specific PPAR knockout mice by crossing CD4-Cre mice with mice carrying loxP sites within the PPAR gene (CD4-PPAR KO ; Fig. S2 ). In the absence of PPAR, Th17 differentiation was strongly increased when compared with wild-type CD4 + T cells ( Fig. 1 d) , indicating that PPAR serves as a T cell-intrinsic brake of Th17 differentiation under physiological conditions. Accordingly, Th1 differentiation was not altered in CD4-PPAR KO T cells (Fig. 1 d) . Interestingly, the endogenous PPAR agonist 13s-HODE, a linoleic acid derivative (Huang et al., 1999) , equally suppressed Th17, but not Th1, differentiation ( Fig. 1 d) , further indicating that PPAR activity limits Th17 differentiation under physiological conditions. Given the fact that 12/15-lipoxygenase is expressed in T cells (Vanderhoek, 1988) , it is reasonable to assume that endogenous ligands produced by T cells themselves serve as a brake for Th17 differentiation in an autocrine fashion. Also, PPAR ligand production by antigen-presenting cells may contribute to local control of Th17 differentiation (Huang et al., 1999) .
We further substantiated the inhibitory effect of PPAR on Th17 differentiation by investigating other classical markers of Th17 cells. In addition to IL-17A, we found that PPAR activation by PIO suppressed expression of TNF and IL-22 ( Fig. 1 e) , as well as IL-17F, IL-21, and IL-23R, in T cells (Fig. 1 f) . Likewise, expression of the chemokine receptor CCR6 and its ligand CCL20 were also strongly controlled by PPAR activation (Fig. 1 g ). This demonstrates that PPAR, indeed, influenced differentiation of Th17 cells rather than merely suppressing IL-17A production.
Selectivity of PPAR for Th17 differentiation
To further characterize the specificity of PPAR on the differentiation of Th17 cells, we evaluated the effect of PIO on cytokine-induced CD4 + T cell differentiation into Th1, Th2, or regulatory T cells. Importantly, PIO did not modulate TGF--mediated induction of Foxp3 + regulatory T cells, IL-4-mediated induction of Th2 cells, or IL-12-mediated induction of Th1 cells (Fig. 2 a) . This is in contrast to the effect of RA, which is a natural ligand of the nuclear RA receptor (Chambon, 1994) that has been shown to reciprocally regulate Th17 and regulatory T cell differentiation (Mucida et al., 2007) . In direct comparison, RA and (Bettelli et al., 2007) . Th17 cells mediate pathology in several mouse models of autoimmunity, such as experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease, and collagen-induced arthritis Murphy et al., 2003; Yen et al., 2006) . Recent studies have addressed the role of Th17 cells in human autoimmunity (Lock et al., 2002; Tzartos et al., 2008) . Th17 differentiation critically depends on TGF-, together with proinflammatory cytokines such as IL-6 or IL-21 (Ivanov et al., 2006; Yang et al., 2008) . The key transcription factor for Th17 differentiation is retinoic acid (RA) receptor-related orphan receptor t (RORt; Ivanov et al., 2006; Manel et al., 2008) . However, little information exists on the T cell-intrinsic molecular mechanisms controlling RORt activity, thus contributing to control of Th17-mediated autoimmunity.
We and others have previously shown that the nuclear receptor peroxisome proliferator-activated receptor  (PPAR) is a negative regulator of dendritic cell maturation and function, thereby contributing to CD4 + T cell anergy in vivo (Klotz et al., 2007; Szatmari et al., 2007) . PPAR has also been reported to influence the function of Th cell clones (Clark et al., 2000) ; however, the influence of PPAR on Th differentiation has not yet been addressed. Upon ligand binding, PPAR heterodimerizes with the retinoid X receptor and binds to the PPAR response elements (PPRE) located in the promotor region of target genes (Pascual et al., 2005; Glass and Ogawa, 2006) . Additionally, the antiinflammatory effects of PPAR are mediated by negative interference with proinflammatory cell signaling, e.g., stabilization of corepressor complexes, such as nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT; Pascual et al., 2005; Straus and Glass, 2007) . PPAR agonists include endogenous ligands such as the linoleic acid derivative 13s-hydroxyoctadecadienoic acid (HODE) produced by 12/15-lipoxygenase, as well as several synthetic agonistic ligands such as the antidiabetic thiazolidinediones, e.g., pioglitazone (PIO; Huang et al., 1999; Straus and Glass, 2007) . Previous studies demonstrated a beneficial role of PPAR in EAE (Niino et al., 2001; Diab et al., 2002; Feinstein et al., 2002) . These findings prompted us to address the question of whether PPAR is involved in the T cellintrinsic control of Th17 responses.
RESULTS AND DISCUSSION

Control of Th17 differentiation by PPAR
We first investigated the influence of PPAR on the Th17 responses during MOG-induced EAE. Pharmacological activation of PPAR with PIO in vivo ameliorated the disease course over the entire observation period (Fig. 1 a) , as previously reported (Niino et al., 2001; Diab et al., 2002; Feinstein et al., 2002) . Importantly, CD4 + T cells isolated from the central nervous system (CNS) of PIO-treated EAE mice at day 17 after disease induction produced significantly less IL-17A after PMA/ionomycin restimulation (Fig. 1 b) . This prompted us to investigate in more detail the influence of PPAR on the function of autoreactive MOG-specific T cells.
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ported (Iwata et al., 2003) . Collectively, these data indicate that distinct molecular mechanisms were involved in PPAR-mediated, as compared with RA-mediated, control of T cell differentiation.
We next investigated whether PPAR also affected expression of the key transcription factors determining CD4 + T cell differentiation. PPAR-activation selectively suppressed TGF-/IL-6-mediated expression of RORt, the transcription factor PIO both efficiently suppressed Th17 differentiation, whereas RA but not PIO induced TGF--mediated expression of Foxp3 (Fig. 2 a) . Accordingly, CD4-PPAR KO T cells did not show altered TGF--mediated Foxp3-induction (unpublished data). A further distinction between RA and PIO was observed on Th1 differentiation, as RA slightly but significantly impeded IL-12-mediated induction of IFN- expression in T cells (Fig. 2 a) , as has been previously re- 2008). Furthermore, several groups have reported that the aryl hydrocarbon receptor elicits either regulatory T cell or Th17 responses when activated by distinct ligands; however, the underlying mechanisms do not seem to involve RORt regulation (Quintana et al., 2008; Veldhoen et al., 2008) . Additionally, the nuclear orphan receptor NR2F6 seems to regulate Th17-dependent autoimmunity, but with no apparent involvement of RORt (Hermann-Kleiter et al., 2008) . It required for Th17 induction, whereas the expression of the transcription factors determining Th1, Th2, and regulatory T cell differentiation, i.e., T-bet, GATA-3, and FoxP3, was not influenced by PIO (Fig. 2 b) , again confirming that PPAR acted specifically on the differentiation of Th17 cells. Other transcriptional regulators have been reported to influence Th17 differentiation. Foxp3 has been shown to directly antagonize RORt activity, and thus prevent Th17 differentiation (Zhou et al., Figure 2 . Selectivity of PPAR for Th17 differentiation. (a) CD4 + T cells were subjected to Th1, Th2, Th17, and regulatory T cell differentiation protocols, as described in the Materials and methods section, and the influence of RA and PIO on the induction of lineage markers was determined by flow cytometry and analyzed as described in Materials and methods. (b) CD4 + T cell differentiation was induced as described in Materials and methods, and the influence of PIO on expression of the lineage-determining transcription factors T-bet, GATA-3, RORt, and Foxp3 was determined by quantitative realtime PCR and normalized to -actin levels after 48 h. Data in a and b are representative of at least three independent experiments. illustrate the dynamic range of PPAR-mediated control of Th17 differentiation. We substantiated the influence of PPAR activation on RORt expression using reporter mice, which express GFP under control of the RORc(t) promoter (Lochner et al., 2008) . In such T cells, we observed that PIO strongly reduced TGF-/IL-6-mediated GFP-expression (Fig. 3 b) . Importantly, both the frequency of GFP pos T cells and the mean fluorescence intensity of GFP-expressing T cells were reduced by PIO (Fig. 3, b and c) . These results indicated that most CD4 + T cells failed to express RORt under the influence of PPAR activation, thus giving rise to less Th17 cells. Furthermore, the decreased mean fluorescence intensity of GFP in PIO-treated RORc(t) reporter T cells (Fig. 3 c) revealed that upon PPAR activation there was less GFP, i.e., RORt, on a per cell basis, suggesting that PPAR reduced RORt transcription on a single-cell level.
can therefore be concluded that several receptors are involved in the T cell-intrinsic control of Th17-responses, but that the molecular pathways involved in these processes are distinct. Even among the family of PPARs, the regulatory effect on Th17 differentiation is not a general feature, as lack of PPAR in T cells did not result in altered IL-17 expression levels (Dunn et al., 2007) .
PPAR inhibits Th17 differentiation by controlling RORt induction
We next evaluated whether PPAR influenced RORt expression in T cells. In PPAR KO T cells, we observed enhanced cytokine-induced RORt induction compared with PPAR WT T cells (Fig. 3 a) . The suppressive effect of PPAR activation by PIO on the one hand and the increased expression of RORt in PPAR KO T cells on the other hand (Fig. S3 a) , and interaction of recombinant PPAR with the murine RORt promoter was determined by surface plasmon resonance analysis. Sensograms show the binding of indicated concentrations of PPAR at either the RORt promoter or the murine AP2 promoter containing a bona fide PPRE site as positive control; shown are a representative sensogram (left) and a quantitative analysis (right). The bar graph shows mean ± SEM from three independent experiments. (e) Signal-dependent clearance of SMRT from the RORt promoter is prevented by PIO. ChIP experiments were performed for SMRT in mock-treated CD4 + T cells and in CD4 + T cells stimulated with TGF-/IL6 in the presence or absence of PIO. ChIP assay was performed with SMRT or IgG for control of specificity. Immunoprecipitated DNA was analyzed by quantitative PCR using primers specific for the RORt promoter; as control, binding of SMRT to a nonrelated DNA control (exon 1 of the ROR gene) was investigated and set as 1. Two independent experiments were performed, and mean results ± SEM are shown. The control of PPAR over RORt transcription led us to examine whether the RORt promoter contained a bona fide PPAR-binding site (PPRE), which might permit direct interaction of PPAR with the RORt promoter. Bioinformatic analysis did not reveal any known PPRE sequence within the mouse RORt promoter (unpublished data). In addition, we excluded direct interaction of PPAR with the RORt promoter by examining the binding of recombinant PPAR to the full-length RORt promoter using surface plasmon resonance analysis. In contrast to strong and specific binding of PPAR to the AP2 promoter, which contains a PPRE site (Frohnert et al., 1999) , we did not observe significant binding to the RORt promoter (Fig. 3 d) .
The lack of a high-affinity PPAR binding site in the RORt promoter raised the possibility that PPAR might negatively regulate RORt transcription through a transrepression mechanism that does not require direct DNA binding. One such mechanism involves the ability of ligandactivated PPAR to inhibit signal-dependent clearance of NCoR or SMRT corepressor complexes from promoters of regulated genes (Pascual et al., 2005; Ghisletti et al., 2009 ). To investigate this possibility, we used chromatin immunoprecipitation (ChIP) to screen of genomic sequences surrounding the RORt promoter (unpublished data) for corepressor binding. These studies revealed the binding of the corepressor SMRT, but not NCoR, at the RORt promoter in unstimulated mouse CD4 + T cells (Fig. 3 e and  not depicted) . Importantly, stimulation of CD4 + T cells with TGF- and IL-6 resulted in rapid and nearly complete loss of SMRT from the RORt promoter (Fig. 3 e) , indicating that SMRT clearance precedes RORt activation. Interestingly, this cytokine-induced clearance of SMRT from the RORt promoter was prevented by the PPAR agonist PIO (Fig. 3 e) . These data suggest that the retention of SMRT results in persistent repression of RORt in the presence of activating cytokines, and are consistent with prior studies demonstrating that PPAR suppresses activation of inflammatory response genes in macrophages by preventing NCoR/SMRT turnover (Ghisletti et al., 2009) . Interference of SMRT clearance from the RORt promoter thus provides a previously unrecognized mechanism by which ligand-activated PPAR may control Th17 differentiation in T cells. However, these findings do not exclude other mechanisms, such as modulation of STAT3 or IRF4 signaling (Nurieva et al., 2007; Huber et al., 2008) .
PPAR in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo
To analyze whether PPAR is involved in T cell-intrinsic control of CNS autoimmunity, we induced EAE in CD4-PPAR KO mice and wild-type littermates. CD4-PPAR KO mice showed a significantly earlier onset and aggravated disease course during the initial T cell-dependent phase of disease until d15 (Fig. 4 a) . However, this difference was not observed in the effector phase, when disease activity is mainly determined by a local inflammatory response within the CNS governed by microglial cells (Heppner et al., 2005) . Disease activity in CD4-PPAR KO mice directly correlated with the total numbers of infiltrating CD4 + T cells in the CNS (Fig. 4 b) . Both at the beginning of clinical disease activity (day 8), and at the peak of disease in CD4-PPAR KO mice (day 13), we found significantly increased total CD4 + T cell numbers in the CNS. Later (day 18) disease score and T cell influx were not different from wildtype littermates. As expected, PIO-treated wild-type mice exhibited decreased T cell numbers within the CNS at all time points investigated (Fig. 4 b) . Importantly, at the peak of disease in CD4-PPAR KO mice, the frequency of MOG peptide-specific, IL-17-producing CD4 + T cells in the CNS was increased by threefold, which, together with the increase in T cell influx, enhanced the numbers of IL-17-producing autoreactive T cells within the target organ by nearly fivefold (Fig. 4, b and c) . In contrast, there was no alteration in antigen-specific IFN--producing CD4 + T cells in these mice (Fig. 4 c) .
The clinical symptoms and antigen-specific Th17 responses in CD4-PPAR KO mice both revealed that the kinetics of CNS autoimmunity in vivo were modulated by PPAR in a T cell-intrinsic fashion. There was pronounced accumulation of IL-17-producing T cells in the CNS compared with the spleen in CD4-PPAR KO mice (Fig. 4 c) , which may be caused by guided entry of Th17 cells into the CNS. A recent study demonstrated that CCR6-expressing Th17 cells function as "pioneer" cells, enabling immune cell entry into the CNS at the beginning of CNS autoimmunity (Reboldi et al., 2009) . In this regard, the control of expression of both CCR6 and its ligand CCL20 by PPAR activation (Fig. 1 g ) may explain the decreased influx of T cells and the reduced disease activity in the CNS of PIO-treated wildtype mice. The protective effect of PIO on disease activity was greatly diminished in CD4-PPAR KO mice (Fig. S4 b) , thus excluding off-target effects that had been reported previously (Chawla et al., 2001 ) and further demonstrating that development, despite its profound effect on Th17 differentiation, lends support for a key but not exclusive role of Th17 cells in CNS inflammation, as previously reported (Yang PPAR expression in T cells was required for full protective effect of PIO on CNS autoimmunity. The observation that PPAR activation in vivo did not entirely protect from EAE et al., 2009) . The persistent Th1 responses, which were not altered by PPAR activation, may explain persistent disease activity, despite diminished Th17 responses.
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As we also observed a significant increase in antigen-specific Th17 cell numbers in the spleen in CD4-PPAR KO mice at the peak of disease (Fig. 4 c) , we next asked whether PPAR influenced Th17 differentiation in vivo at early time points. To this end, we adoptively transferred CD90.2 + CD4 + T cells from OT-II mice, followed by immunization with OVA in CFA. Importantly, PIO treatment of these mice strongly interfered with the expression of activation markers (Fig. 4 d) and IL-17 production (Fig. 4 e) by the adoptively transferred T cells 4 d after immunization; this persisted for longer than 4 d (day 7; not depicted), demonstrating that PPAR controls antigen-specific Th17 differentiation in vivo.
Collectively, the entire range of PPAR-sensitive control of Th17 differentiation in vivo and CNS autoimmunity is reflected by the combination of pharmacological PPAR activation on the one hand and by the absence of PPAR-activity in CD4-PPAR KO mice on the other hand.
PPAR selectively controls Th17 differentiation in T cells from healthy controls (HCs) and MS patients
The protective effects of PPAR on both clinical manifestation and Th17-responses during EAE prompted us to investigate whether T cells from HCs and MS patients were susceptible to treatment with PPAR agonists. Again, we focused on the effect of PPAR activation on T cells by using direct stimulation with TGF-/IL-21 in the absence of antigen-presenting cells. Pharmacologic PPAR activation reduced the frequency of IL-17A-producing CD45RA + CD4 + T cells both in HC and MS patients (Fig. 5 a) . Although in our experiments there was no apparent difference in Th17 differentiation between HC and MS patients in vitro, it is important to note that PIO-treatment was equally effective in potent suppression of IL-17A release from T cells (Fig. 5 b) . Moreover, no influence of PIO was observed during IFN- production (Fig. 5 b) . Pharmacologic PPAR activation prevented Th17 differentiation, as demonstrated by diminished expression of the Th17 markers IL-17F, IL-21, IL-22, and IL-23R upon PIO treatment (Fig. 5 c) . Importantly, the specific effect of PPAR activation on Th17 induction in human CD4 + T cells was further illustrated by selective regulation of RORt expression, whereas T-bet and GATA-3 expression were not altered by PIO (Fig. 5 d) .
In summary, we identify PPAR as a defined molecular target to selectively modulate Th17 differentiation in a T cellintrinsic fashion, which opens up new possibilities for specific immunointervention in Th17-mediated autoimmune diseases such as MS.
MATERIALS AND METHODS
Mice. CD4-specific PPAR knockout mice with the genotype PPAR fl/fl CD4-Cre +/ (i.e., CD4-PPAR KO mice) were generated by crossing PPAR fl/fl mice (He et al., 2003) with CD4-Cre +/ transgenic mice expressing Cre recombinase under control of the CD4 enhancer/promoter/silencer (Lee et al., 2001) . Expression of Cre recombinase in CD4-expressing T cells leads to recombination at two loxP sites flanking exons two and three of the PPAR gene, thus resulting in a T cell-specific PPAR knockout (Fig. S1 ). We did not observe any alteration in immune cell frequencies in these mice (Fig. S1 ). CD90.2 + CD4-TCR transgenic OT II mice specific for the peptide ova 323-339 , BAC-transgenic Rorc(t)-GFP TG mice, and C57BL/6 mice (Charles River Laboratories) were maintained under specific pathogen-free conditions. All animal experiments were performed according to the guidelines of the animal ethics committee and were approved by the government authorities of Nordrhein-Westfalen, Germany.
Cell culture and adoptive cell transfer. PBMCs were obtained from the peripheral blood of healthy volunteers or from patients with clinically definite relapsing-remitting MS according to the McDonald criteria, approved by the local Ethics Committee. CD4 + CD45RA + CD45RO  CD25  T cells were isolated by immunomagnetic cell separation using an AutoMACS (Miltenyi Biotec) and stimulated with plate-bound 1.5 µg/ml CD3 antibody (OKT3), 1 µg/ml CD28 antibody (28.2), 2.5 ng/ml TGF- (R&D Systems) and 12.5 ng/ml IL-21 (Cell Systems) for 7 d in serum-free X-VIVO 15 medium (Biowhittaker; Yang et al., 2008) . 10 µM PIO (Enzo Biochem, Inc.) was added when indicated. Mouse splenic CD4 + T cells were isolated by immunomagnetic separation using CD4-MACS beads (Miltenyi Biotec) and stimulated with plate-bound 4 µg/ml CD3 antibody (145-2C11) and 4 µg/ml CD28 antibody (3751) together with 5 ng/ml TGF- and 20 ng/ml IL-6 (PeproTech) for Th17 differentiation; with IL-12 (10 ng/ml) for Th1 differentiation; with IL-4 (10 ng/ml) for Th2 differentiation or with TGF- alone (5 ng/ml) for regulatory T cell differentiation. In one experiment, MACS-isolated splenic DCs from B6 mice were cocultured with T cells in the presence of antigen (10 µg/ml ova [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] ). The endogenous PPAR agonist 13s-HODE (Cayman Chemicals) was used at a concentration of 10 µM. All-trans RA (Sigma-Aldrich) was used at a 1 µM concentration. TCR transgenic CD4 + T cells from OTII mice bearing the congenic marker CD90.1 + were isolated and 10 6 cells were adoptively transferred by bolus i.v. injection in 200 µl PBS into wild-type CD90.2 + congenic mice.
EAE. EAE was induced by s.c. injecting 50 µg MOG 35-55 peptide (BIOTREND) emulsified in CFA (Difco) with 8 mg/ml heat-inactivated Mycobacterium tuberculosis and two i.p. injections of 200ng Bordetella pertussis toxin (List Biologicals) on days 0 and 2. Clinical assessment of EAE was performed daily using a scale ranging from 0 to 6: 0, clinically normal; 1, reduced tone of tail; 2, ataxia and/or slight hind-limb paresis; 3, severe hind-limb paresis; 4, hind limb plegia; 5, tetraparesis; 6, moribund/dead animals. Cell analysis from spleens and CNS was performed as indicated.
Real-time RT-PCR. Cells were washed with ice-cold PBS, and RNA extraction was performed using the RNeasy mini kit (QIAGEN) according to the manufacturer's protocol. Reverse transcription of RNA was performed with SuperScript III (Invitrogen). cDNA was analyzed using FAMlabeled TaqMan probes obtained from Applied Biosystems and used according to the manufacturer's recommendations. mRNA expression levels of RORt, T-bet, GATA-3, and Foxp3, as well as the Th17 markers IL-17A, IL17F, IL-21, IL-22, and IL-23R, were assessed using gene-specific primers. Gene expression was assessed in triplicates and normalized to -actin. Amplification of cDNA was performed on an AbiPrism 7900 HT cycler (Applied Biosystems).
Cytokine detection. Mouse IL-17A and Foxp3 protein expression were examined by intracellular staining according to the manufacturer's protocol. MOG-specific IL-17 and IFN- production was analyzed by specific ELISpot assays according to the manufacturer's procedures (R&D Systems), and spot numbers were counted with an automated ELISpot reader (BIO-READER-2000) . Human IL-17A and IFN- protein levels from cell culture supernatants were determined by ELISA (R&D Systems).
